Pharmacological inhibition of type 5 adenylyl cyclase, a model for healthful aging, enhanced exercise capacity and glucose tolerance
Exploration of Endocrine and Metabolic Diseases · 2025
DOI: 10.37349/eemd.2025.101445 ↗Kurz gefasst
Fachartikel in der Zeitschrift Exploration of Endocrine and Metabolic Diseases, 2025. Verfasst von Dorothy E. Vatner und 5 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Adenylyl cyclase 5 knockout (AC5 KO) is a healthful longevity model; not only do the AC5 KO mice live a third longer than wild-type (WT) mice, but they are also protected against obesity, diabetes, heart failure, and exercise intolerance, mediated by anti-apoptosis, cell survival, myocardial biogenesis, and anti-oxidative stress mechanisms. To translate these salutary effects to the clinics, we developed a drug, C90, which recapitulates the AC5 KO model of healthful longevity. We then examined its effects on glucose tolerance and exercise capacity. C90 (30 mg/kg/day) or vehicle was chronically administered to age-matched C57BL/6 mice via an osmotic pump. The WT mice receiving C90 exhibited improved glucose tolerance, following glucose i.v. injection, when compared to the vehicle. Furthermore, the C90-treated mice had a lower fasting glucose level when compared to the vehicle-treated mice (113 ± 6.5 mg/dL vs. 129 ± 4.2 mg/dL, p < 0.05). Additionally, the WT group that received C90 exhibited greater exercise capacity, reflected by longer running distance (384 ± 27 m vs. 253 ± 16 m, p < 0.05) and greater work to exhaustion (18.1 ± 1.5 J vs. 12.4 ± 0.7 J, p < 0.05) than mice receiving vehicle. In view of these findings, C90 is an excellent candidate for clinical development as an effective pharmacological treatment for glucose intolerance and enhancing exercise performance.
Zitieren
APA
Vatner, D. E., Bravo, C. A., Oydanich, M., Zhang, J., Roberge, J. Y., & Vatner, S. F. (2025). Pharmacological inhibition of type 5 adenylyl cyclase, a model for healthful aging, enhanced exercise capacity and glucose tolerance. Exploration of Endocrine and Metabolic Diseases. https://doi.org/10.37349/eemd.2025.101445
Vancouver
Vatner DE, Bravo CA, Oydanich M, Zhang J, Roberge JY, Vatner SF. Pharmacological inhibition of type 5 adenylyl cyclase, a model for healthful aging, enhanced exercise capacity and glucose tolerance. Exploration of Endocrine and Metabolic Diseases. 2025. doi:10.37349/eemd.2025.101445
BibTeX
@article{Vatner2025,
author = {Vatner, Dorothy E. and Bravo, Claudio A. and Oydanich, Marko and Zhang, Jie and Roberge, Jacques Y. and Vatner, Stephen F.},
title = {Pharmacological inhibition of type 5 adenylyl cyclase, a model for healthful aging, enhanced exercise capacity and glucose tolerance},
journal = {Exploration of Endocrine and Metabolic Diseases},
year = {2025},
doi = {10.37349/eemd.2025.101445}
}
EUVIMED